RHOA and neoplasm: In the context of melanoma, somatic splice-site mutation of TMEM216 suggests potential tumor suppressor function and sets the RHOA/GNA12 pathway apart from the Gs-protein/MAPK pathway by mutual exclusivity of TMEM216 towards known oncogenes NRAS and RAC1 (Supplementary information 3).